MYRELEZ

This brand name is authorized in Estonia, Finland, Ireland, Lithuania, Poland.

Active ingredients

The drug MYRELEZ contains one active pharmaceutical ingredient (API):

1	Lanreotide UNII IEU56G3J9C - LANREOTIDE ACETATE
	Lanreotide is an octapeptide analogue of natural somatostatin. Like somatostatin, lanreotide is an inhibitor of various endocrine, neuroendocrine, exocrine and paracrine functions.
	Read more about Lanreotide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MYRELEZ Solution for injection	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H01CB03	Lanreotide	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CB Somatostatin and analogues
Discover more medicines within H01CB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1791154, 1791165, 1791176, 1833768, 1833779, 1833780
FI	Lääkealan turvallisuus- ja kehittämiskeskus	392697, 449026, 549549
LT	Valstybinė vaistų kontrolės tarnyba	1092652, 1092653, 1092654, 1092655, 1092656, 1092657
PL	Rejestru Produktów Leczniczych	100418950, 100418966, 100418972